Biodel - Marlboro für das Depot?

Biodel Appoints Ms. Arlene M. Morris to Its Board of Directors






DANBURY, CT--(Marketwired - May 18, 2015) - Biodel Inc. (NASDAQ: BIOD) today announced the appointment of Ms. Arlene M. Morris to its board of directors.

Chairman of the Board, Dr. Ira Lieberman stated, "Arlene's background and extensive experience in the pharmaceutical and biotechnology industries, coupled with her leadership and board experience will be a great complement to our existing board."

Ms. Morris was recently the President and CEO of Syndax, a Boston based epigenetic company. Previously, she was the president, chief executive officer and member of the board of directors of Affymax, Inc. During her eight years at Affymax, Ms. Morris led the company through the development of OMONTYS peginesatide, a strategic collaboration with Takeda, an initial public offering, and several follow on offerings.

Prior to Affymax, Ms. Morris was the president and CEO of Clearview Projects, an advisory firm which counsels biopharmaceutical and biotechnology companies on strategic transactions. Before that, she was the senior vice president of business development at Coulter Pharmaceuticals, Inc., where she completed numerous transactions including a $1.0 billion merger between Corixa and Coulter. She was also the vice president of business development at Scios where she completed numerous transactions. Ms. Morris began her career at Johnson & Johnson as a sales representative, rising to vice president of business development.

Ms. Morris serves on the board of directors of Neovacs SA and the Medical University of South Carolina Foundation for Research and Development. She received her bachelor's degree in biology from Carlow College.

"I am honored to join the board of Biodel. I am very excited about Biodel's pipeline and look forward to working with the board and management team over the coming years," said Ms. Morris.

"Arlene's extensive leadership and operational experience will help guide us as we look to transition Biodel to a late-stage product development company over the next twelve to eighteen months," added Dr. Errol De Souza, president and chief executive officer of Biodel.

Ms. Julia R. Brown has been a member of our board of directors since April 2012.  Ms. Julia R. Brown has held a variety of executive positions over her 40 year career in the pharmaceutical industry.  From 2000-2003, Ms. Brown was Executive Vice President of Amylin Pharmaceuticals, Inc., responsible for commercial operations.  She served as Advisor to the CEO until 2008.  Prior to joining Amylin, Ms. Brown was Executive Vice President of Dura Pharmaceuticals, Inc.  Ms. Brown spent over 25 years with Eli Lilly and Company in progressively more senior roles including Vice President of IVAC Corporation and General Manager of its Vital Signs Division and Vice President of Worldwide Marketing for Hybritech.

Ms. Brown has previously served on the board of directors of seven other development stage pharmaceutical or biopharmaceutical companies.  She is Chairperson of Corporate Directors Forum?an organization dedicated to high standards of professionalism in corporate governance. Ms. Brown is a d of trustee of the UC San Diego Foundation and is chair emerita.  She is a member of the board of CONNECT, an organization that fosters innovation, entrepreneurship and the formation of new companies in southern California.  Ms. Brown is a graduate of Louisiana Tech University where she studied microbiology and biochemistry.

nmM

KK